Navigation Links
Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments
Date:11/9/2010

ially successful or will effectively enhance our businesses or their market value, or that the MedPodium product line can be successfully broadened to include additional healthy lifestyle opportunities, or that we can effectively promote commercialization of our products on our own or through third parties; that improvements in the formulation or use of Generx will be commercially practicable, or that Generx could be successfully advanced as a therapeutic in developing markets or that the results of studies in such markets could be used to advance or broaden the commercialization of Generx in the U.S. or other markets; that Nitric Oxide or other technologies we investigate can be used to effectively expand or improve our product portfolio; that our product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive; that our clinical study programs can be conducted and completed in an efficient and successful manner; that we can develop a DNA-based orthobiologics product portfolio; that the FDA or other regulatory clearances or other certifications, or other commercialization efforts will be successful or will effectively enhance our businesses or their market value; that our products or product candidates will prove to be sufficiently safe and effective after introduction into a broader patient population; or that third parties on whom we depend will perform as anticipated.

Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our depen
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Cardium to Present at the LifeTech Capital Miami Medical Investors Conference
2. Cardium Gains Exclusive Access to Novel Polymer-Based Nitric Oxide Technology for Expansion of Wound Healing Product Portfolio
3. Cardium to Present at 10th Annual Biotech in Europe Investor Forum
4. Cardium Regains Listing Compliance With NYSE Amex
5. Cardium to Present at MDB Capital Groups 2010 Bright Lights Conference
6. Cardiums Exchange Listing Compliance Plan Accepted by NYSE AMEX
7. Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments
8. Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds
9. Cardium Completes $6.0 Million Registered Direct Offering
10. Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors
11. Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 Selexis SA, ... mammalian Research Cell Banks (RCBs) used for drug discovery ... Cell Banks will include Next-Generation Sequencing (NGS) ... architecture de-risks biologic manufacturing by ensuring the integrity of ...
(Date:1/22/2015)... CAMBRIDGE, Mass. , Jan. 22, 2015   GenoSpace , ... suite of tools to enable the broad use of genomic, ... today announced the appointment of Michelle Munson , CEO ... independent director. Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
(Date:12/24/2014)...  Vermillion, Inc. (Nasdaq:   VRML), a bio-analytical solutions ... the Company closed its previously announced private placement ... W. Schuler , Birchview Fund LLC and several ... offering expenses.  The proceeds will be used for ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 ... designed to introduce cutting edge communication technology, provide ... platform upgrades. This webinar series demonstrates online communication ... to leverage web conferencing’s most innovative and powerful ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2GenoSpace Expands Board with Appointment of Michelle Munson 2Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3
... ,, CAMBRIDGE, England , May 25, ... ( Cambridge, UK ) announced today,an extension of the agreement under which ... , , ... Miles Congreve , Head of Chemistry said, "We are happy to ...
... China , May 25 /PRNewswire-Asia-FirstCall/ -- Biostar,Pharmaceuticals, Inc. (Nasdaq: ... leading over-the-counter Hepatitis B medicine,Xin Aoxing Oleanolic Acid Capsule ("Xin Aoxing"), ... it has,commenced assembly of its production line for its proprietary Zushima ... ...
... May 25 Fibrocell Science, Inc. (OTC Bulletin ... autologous cell therapies for aesthetic, medical and scientific applications, announced ... Irish Voice newspaper and Irish America Magazine ... Officer Declan Daly as a member of the ...
Cached Biology Technology:Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration With Oxygen Healthcare (O2h) 2Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration With Oxygen Healthcare (O2h) 3Biostar Pharmaceuticals, Inc. Begins Assembly of New Production Line 2Biostar Pharmaceuticals, Inc. Begins Assembly of New Production Line 3Biostar Pharmaceuticals, Inc. Begins Assembly of New Production Line 4The Irish Government and the Irish Voice Recognize Fibrocell Science, Inc.'s Declan Daly as 'Irish Life Science 50' Member 2
(Date:1/22/2015)... 2015 , Europe,s ... The European Patent Office to present a video retrospective of the ... be featured: Christofer Toumazou and Sophie Wilson   ... winners of the Award   Starting on 22 January ...
(Date:12/22/2014)... 2014  NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... the growing mobile commerce market, announces it has retained famous ... the 2015 International CES debut of the Wocket™ biometric smart ... at the NXT-ID booth January 6th and 7 th , ...
(Date:12/19/2014)...  23andMe, Inc., the leading personal genetics company, today announced the ... ancestry of individuals from across the United States ... four hundred years ago, the United States ... different continents. This study illuminates how American history and the ...
Breaking Biology News(10 mins):Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 423andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... led by Chu Chen, PhD, Associate Professor of Neuroscience at ... called Monoacylglycerol lipase (MAGL) as a new therapeutic target to ... November 1, 2012 in the Online Now section of the ... inactivation of MAGL, best known for its role in degrading ...
... delves into the unexpected properties of life at the nanoscale ... Molecular Machines Extract Order from Chaos," by Peter M. Hoffmann, ... in Wayne State University,s College of Liberal Arts and Sciences, ... and pulleys, atoms and quarks to explain life. ...
... has found that the sensitivity and recovery of UK butterfly populations ... of fragmentation of key habitat types in the landscape. ... , used data on the Ringlet butterfly collected from 79 UK ... spanned a severe drought event in 1995. The study ...
Cached Biology News:LSUHSC research identifies new therapeutic target for Alzheimer's disease 2New book on physics principles by Wayne State professor explains life as we know it 2UK butterfly populations threatened by extreme drought and landscape fragmentation 2
... Mitochondria Derived Activator of Caspase/DIABLO Liquid. ... 7.5 AVOID FREEZE/THAW CYCLES. Amino acid residues 56 ... terminal His•Tag ® sequence was expressed in ... is released along with cytochrome c ...
... JASCO offers a dedicated system for SFC ... LC-1500 series of HPLC instrumentation. JASCO has ... the capability of the system: ,- The ... and extraction procedures using carbon dioxide as ...
... medium was originally formulated to support the ... emperor gum moth,Antherea eucalypti. The medium is ... closely resembleAnthereahemolymph. The cell lines established by ... continuous lines developed. The basal medium, when ...
... trays and universal trays make vessel ... Shaking speed: 40 - ... amplitude Clamps for Erlenmeyer ... including Fernbach flasks Hinged ...
Biology Products: